Trial Profile

A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 26 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saracatinib (Primary) ; Paclitaxel
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms SaPPrOC

Most Recent Events

24 Jan 2014 Accrual to date is 104% according to United Kingdom Clinical Research Network
08 Aug 2013 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
06 Jun 2013 Status changed from active, no longer recruiting to completed, based on the 49th Annual Meeting of the American Society of Clinical Oncology abstract.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com